Drug Database
Back to search

Poland· PL-100311010

Inovelon

A rufinamide product containing rufinamidum, registered in Poland by Eisai GmbH. The same ATC class is registered in 17 of our 19 countries.

ATC N03AF03

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedInovelonATCN03AF03REGISTER NO.PL-100311010PACKS LISTED0CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about rufinamidumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Rufinamide is registered in 17 of 19 countries.

Countries holding a registration under ATC N03AF03 (rufinamide), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 10 of them publish a price we can compare per daily dose
Search rufinamide products by name

Rufinamide · ATC N03AF03

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of rufinamide costs, country by country.

Normalised to the WHO defined daily dose (1.4 g), the median price runs from $7.83 in Switzerland to $12.24 in Italy — a ×1.6 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Rufinamide · price per daily dose (1.4 g)

USD · FX 28 Sept 2026

  • IT Italy$12.24
  • FR France$8.57
  • CH Switzerland$7.83
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Rufinamidum
Manufacturer
Eisai GmbH
Country
Poland (PL)
ATC code
N03AF03
ATC class
Rufinamide
Defined daily dose
1.4 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

238 interactions on record for rufinamide.

Graded by severity as the source publishes them — 232 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check rufinamide against other medicinesHow interaction checks work

Rufinamide · interactions on record

238 records

  • 232 moderate
  • 6 minor

Most severe, free to view

  • MetoclopramideA03FA01moderate
  • OndansetronA04AA01moderate
  • GranisetronA04AA02moderate
  • ThiethylperazinA04AB03moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Rufinamide in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All rufinamide products

Authorised across Europe · EMA

The same active substance is authorised in 6 EEA countries. Names it is sold under:

  • Germany · Rufinamid Actrevo, Rufinamid Micro Labs
  • France · Rufinamide Actrevo, Rufinamide Medipha
  • United Kingdom (Northern Ireland) · Rufinamide, Rufinamide Brown & Burk
  • Iceland · Inovelon
  • Liechtenstein · Inovelon
  • Norway · Inovelon

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/51a6e7d4-d8c4-4465-a665-e815caeba778
GET /v1/drugs/51a6e7d4-d8c4-4465-a665-e815caeba778?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "400 mg",
  "packaging": "Rpz ¦ EU/1/06/378/011 ¦ 89405\n10 tabl.\nRpz ¦ EU/1/06/378/012 ¦ 89406\n30 tabl.\nRpz ¦ EU/1/06/378/013 ¦ 89407\n50 tabl.\nRpz ¦ EU/1/06/378/014 ¦ 89408\n60 tabl.\nRpz ¦ EU/1/06/378/015 ¦ 89409\n100 tabl.\nRpz ¦ EU/1/06/378/016 ¦ 89410\n200 tabl.",
  "substance": "Rufinamidum 400 mg",
  "common_name": "Rufinamidum",
  "pl_product_id": "100311010",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about rufinamide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console